# Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

> **NCT05626478** · PHASE4 · COMPLETED · sponsor: **Nicole Fram M.D.** · enrollment: 50 (actual)

## Conditions studied

- Corneal Edema
- Corneal Defect
- Anterior Chamber Inflammation
- Ocular Pain
- Corneal Staining
- Visual Outcome
- CME - Cystoid Macular Edema

## Interventions

- **DRUG:** Dextenza 0.4Mg Ophthalmic Insert
- **DRUG:** Prednisolone Acetate 1% Oph Susp
- **DRUG:** Prolensa 0.07% Ophthalmic Solution

## Key facts

- **NCT ID:** NCT05626478
- **Lead sponsor:** Nicole Fram M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05626478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05626478, "Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05626478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*